Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Non-Current Liabilities (2020 - 2025)

Bioventus (BVS) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $15.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 33.56% year-over-year to $15.3 million, compared with a TTM value of $15.3 million through Dec 2025, down 33.56%, and an annual FY2025 reading of $15.3 million, down 33.56% over the prior year.
  • Other Non-Current Liabilities was $15.3 million for Q4 2025 at Bioventus, down from $20.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $81.9 million in Q4 2022 and bottomed at $15.3 million in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $26.4 million, with a median of $22.7 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities surged 39.69% in 2022, then tumbled 62.26% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $16.3 million in 2021, then soared by 39.69% to $22.8 million in 2022, then decreased by 20.43% to $18.2 million in 2023, then increased by 27.28% to $23.1 million in 2024, then tumbled by 33.56% to $15.3 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for BVS at $15.3 million in Q4 2025, $20.5 million in Q3 2025, and $21.3 million in Q2 2025.